Researchers sought to assess the risk for COVID-19-related hospitalization or death among patients with immune-mediated inflammatory diseases receiving treatment with tumor necrosis factor inhibitors.
A team of investigators sought to determine the impact on chronic inflammatory diseases such as psoriasis and psoriatic arthritis on sexual life.
Researchers reported integrated results from 24-week, phase 3 randomized clinical trials on the safety and efficacy of risankizumab in patients with active psoriatic arthritis.
The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.
Researchers evaluated the long-term effect of guselkumab on resolution of dactylitis and enthesitis in patients with psoriatic arthritis.
There has been a decrease in hospital discharges for sepsis, skin and soft tissue infections, and urinary tract infections among patients with psoriatic arthritis during the past several years.
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
Cortrophin Gel is a purified adrenocorticotropic hormone.
The DISCOVER-2 trial included 739 biologic-naïve adults with active psoriatic arthritis who were treated and followed for approximately 2 years.
Potential risk factors associated with cognitive impairment in patients with psoriasis are assessed.
